Official Title
Randomized Open Label Study of Standard of Care Plus Intravenous Immunoglobulin (IVIG) Compared to Standard of Care Alone in the Treatment of COVID-19 Infection
Brief Summary

The purpose of this research is to see if Intravenous Immunoglobulin (IVIG) can help reduce respiratory complications (respiratory failure and need for a ventilator) caused by coronavirus disease 2019 (COVID-19). The principal investigator has successfully utilized IVIG for patients infected with the influenza virus. The investigator wants to find out if IVIG is equally effective in COVID-19 infection patients, and if IVIG will give the immune system some help to clear the infection naturally.

Detailed Description

This is an investigator initiated, open label, multicenter, two arm, randomized study to
compare the impact of adding IVIG to the Standard of Care (SOC) to the SOC without IVIG.
Randomization will be 1:1. The goal of this study is to identify whether or not IVIG can halt
the progression to respiratory failure requiring mechanical ventilation in subjects admitted
to the hospital with confirmed COVID-19. The addition of IVIG to the standard of care
treatment for these patients may be beneficial in abating acute lung injury in subjects with
SARSCoV-2 induced hypoxia that results in organ injury.

Completed
SARS-COV2

Drug: Octagam

Standard of Care plus Octagam infusion for 3 days.
Other Name: IVIG

Eligibility Criteria

Inclusion Criteria:

- Confirmed COVID-19 positive test result (including presumptive positive).

- Hospitalization

- Requiring ≥4 liters/min O2 nasal cannula to maintain oxygen saturation ≥ 92%, but not
mechanically ventilated

- Age ≥18 years old.

- Access to a phone in the hospital room or an electronic device that is capable of
receiving phone calls and/or video calls and/or e-mail.

- Able to read/write/speak English or Spanish fluently.

- Subjects must have the capacity to provide consent or an appropriate Legally
Authorized Representative (LAR) to provide informed consent.

provide informed consent, and provide authorization of use and disclosure of personal
health information.

- Negative pregnancy test for women of childbearing potential.

Exclusion Criteria:

- Severe allergy to any IVIG product formulation

- History of DVT, PE, thromboembolic stroke or other thrombotic events

- Hypersensitivity to corn. Octagam® contains maltose which is a sugar derived from
corn.

- Uncontrolled hypertension (SBP>180 mm Hg or DBP>120mmHg)

- Active participant in another research treatment study

- Mechanically ventilated patient

- Code status is Do Not Resuscitate or Do Not Intubate

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
United States
Locations

Sharp Grossmont Hospital
La Mesa, California, United States

Sharp Memorial Hospital
San Diego, California, United States

George Sakoulas, MD, Principal Investigator
Sharp HealthCare

NCT Number
Keywords
Coronavirus
IVIG
Covid-19
MeSH Terms
COVID-19
gamma-Globulins
Immunoglobulins, Intravenous
Rho(D) Immune Globulin